(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 January 2009 (22.01.2009)

PCT

(10) International Publication Number
WO 2009/010299 A8

(51) International Patent Classification:

C07D 401/04 (2006.01)	*A61P 3/10* (2006.01)
C07D 401/14 (2006.01)	*A61P 15/00* (2006.01)
C07D 417/14 (2006.01)	*A61P 35/00* (2006.01)
C07D 453/02 (2006.01)	*A61P 25/00* (2006.01)
A61K 31/44 (2006.01)	*A61P 25/22* (2006.01)
A61P 3/04 (2006.01)	*A61P 25/24* (2006.01)

(21) International Application Number:
PCT/EP2008/005913

(22) International Filing Date: 18 July 2008 (18.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/950,676	19 July 2007 (19.07.2007)	US
07014219.5	19 July 2007 (19.07.2007)	EP

(71) Applicant *(for all designated States except US)*: **SANTHERA PHARMACEUTICALS (SCHWEIZ) AG** [CH/CH]; Hammerstrasse 47, CH-4410 Liestal (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HENNEBÖHLE, Marco** [DE/DE]; Schillerstrasse 26, 79618 Rheinfelden (DE). **HERZNER, Holger** [DE/DE]; Luckestrasse 16, 79595 Rümmingen (DE). **SOEBERDT, Michael** [DE/DE]; Kronenstrasse 18, 79618 Rheinfelden (DE). **WEYERMANN, Philipp** [CH/CH]; Auweg 35, CH-4450 Sissach (CH). **NORDHOFF, Sonja** [DE/CH]; Baselstrasse 103, CH-4144 Arlesheim (CH). **FEURER, Achim** [DE/DE]; Eselacker 1, 79424 Auggen (DE). **DEPPE, Holger** [DE/CH]; Karl Barth Platz 9, CH-4052 Basel (CH). **SIENDT, Hervé** [FR/FR]; 2, rue des Vergers, F-68220 Ranspach-le-Haut (FR). **TERINEK, Miroslav** [CZ/CH]; Rüttelistrasse 13, CH-4416 Bubendorf (CH). **RUMMEY, Christian** [DE/CH]; Güterstrasse 203, CH-4053 Basel (CH).


(74) Agent: **GOLDBACH, Klara**; Grünecker, Kinkeldey, Stockmair & Schwanhäusser, Leopoldstrasse 4, 80802 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS



(I)

(57) Abstract: The present invention relates to substituted heteroarylpiperidine derivative (I) as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

WO 2009/010299 A8

Published:
— *with international search report*

(48) Date of publication of this corrected version:
2 April 2009

(15) Information about Correction:
see Notice of 2 April 2009